November 2019 updates to the website

The website has now been updated following November’s LSCMMG

The following drugs have been added/updated:

Fidaxomicin (Dificlir ®) — Treatment of Clostridium difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults

Stiripentol (Diacomit®) — Adjunctive therapy of refractory generalised tonic-clonic seizures in patients over the age of 18 years who were previously diagnosed with severe myoclonic epilepsy in infancy (Dravet syndrome) whose seizures are not adequately controlled with clobazam and valproate

Xeomin (botulinum neurotoxin type A)— For treating chronic sialorrhoea (NICE TA 605)

Rivaroxaban — For preventing atherothrombotic events in people with coronary or peripheral artery disease (NICE TA 607)

Sodium Zirconium Cyclosilicate  — for treating hyperkalaemia (NICE TA 599)

The following guidelines have been added/updated:

Rheumatoid Arthritis Pathway (Version 3.0) — Guideline — Update

Algorithm For Antihyperglycaemic Therapy In Adults With Type II (Version 1.5) — Guideline — Update

Testosterone (Version 1.1) — Shared-Care Guideline — Update

Over the Counter (OTC) Items that should not be Routinely Prescribed in Primary Care Policy — New

The following Items will be updated and added to the website following January’s Joint Committee of CCGs (JCCCG) Meeting

Cariprazine (Reagila ®) — Treatment of schizophrenia in adult patients